ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Bioorthogonal Sonodynamic Plug-and-Play Targeting Chimeras (SDPTAC) for Precise Targeted Protein Degradation.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- In Situ Bioorthogonal Synthesis of PROTACs via Dual-Responsive Cleavage for Synergistic Photo-Immunotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Delivering Degradation: Nanomedicine and Programmable Proximity Platforms for Targeted Protein Degradation.Pharmaceutics · 2026Review
- Bioorthogonal Sonodynamic Plug-and-Play Targeting Chimeras (SDPTAC) for Precise Targeted Protein Degradation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Targeted protein degradation (TPD) offers powerful therapeutic opportunities but is limited by poor tissue penetration and E3 ligase dependence. Herein, we develop Sonodynamic Plug-and-Play Targeting Chimeras (SDPTAC), an ultrasound (US)-activated, bioorthogonal strategy for in situ protein degradation. SDPTAC assembles via an inverse electron-demand Diels-Alder (IEDDA) click reaction between a sonosensitizer and tetrazine-tagged ligands, generating reactive oxygen species (ROS) upon US to degrade bound proteins. This modular platform enabled efficient degradation of nuclear (bromodomain-containing protein 4, BRD4), cytosolic (nicotinamide phosphoribosyl transferase, NAMPT), and membrane (discoidin domain receptor 1, DDR1) targets, suppressed oncogenic signaling, and achieved nearly complete tumor growth inhibition in vivo with negligible toxicity. SDPTAC thus establishes a versatile, deep-penetrating, and clinically translatable approach for noninvasive protein modulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.